Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and CRISPR Therapeutics AG

A Tale of Two Giants: SG&A Expenses in the Pharmaceutical Industry

In the ever-evolving landscape of the pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: Merck & Co., Inc. and CRISPR Therapeutics AG, from 2014 to 2023.

Merck, a stalwart in the pharmaceutical world, consistently reported SG&A expenses averaging around $10 billion annually. Despite fluctuations, their expenses remained relatively stable, reflecting a robust operational strategy. In contrast, CRISPR Therapeutics, a pioneer in gene-editing technology, exhibited a dynamic growth trajectory. Their SG&A expenses surged by over 1,400% from 2014 to 2021, highlighting their aggressive expansion and investment in innovation.

This comparative analysis underscores the diverse strategies employed by established and emerging players in the pharmaceutical sector, offering valuable insights into their operational priorities.